Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PSEN1 | P49768 | 11/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 11/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 11/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 11/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 11/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 11/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | TSPO | P30536 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5151937 | 0.97 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAPSEN1PSEN2APH1B | |
| SCHEMBL5149628 | 0.87 | PSEN1 (0.50) | SMN1; SMN2LMNAPSEN1PSEN2APH1B | |
| SCHEMBL5149343 | 0.87 | MAPT (0.55) | LMNAPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5149338 | 0.86 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAPSEN1PSEN2APH1B | |
| SCHEMBL5314913 | 0.85 | LMNA (0.53) | SMN1; SMN2LMNAPSEN1PSEN2APH1B | |
| SCHEMBL5317818 | 0.85 | PSEN1 (0.53) | LMNAPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5151346 | 0.85 | PSEN1 (0.53) | SMN1; SMN2LMNAPSEN1PSEN2APH1B | |
| SCHEMBL5151343 | 0.84 | KMT2A (0.53) | SMN1; SMN2LMNAPSEN1PSEN2APH1B | |
| SCHEMBL5156647 | 0.84 | MAPT (0.56) | LMNAPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5154949 | 0.84 | LMNA (0.54) | SMN1; SMN2LMNAPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197524-A1 | Fluorenes and carbazoles as ligands of the EP2 receptor | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-08-23 | — | — | US | claimed |
| WO-2007071456-A1 | FLUORENES AND CARBAZOLES AS LIGANDS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-28 | — | — | WO | claimed |
| US-20070197524-A1 | Fluorenes and carbazoles as ligands of the EP2 receptor | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197524-A1 | Fluorenes and carbazoles as ligands of the EP2 receptor | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197524-A1 | Fluorenes and carbazoles as ligands of the EP2 receptor | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-08-23 | — | — | US | disclosed |
| WO-2007071456-A1 | FLUORENES AND CARBAZOLES AS LIGANDS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197524-A1 | Fluorenes and carbazoles as ligands of the EP2 receptor | PTGER2, PTGER1, PTGDR2 | SMN1; SMN2 3880/4885LMNA 2756/4885PSEN1 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.